HCPCS code J1380 – Estradiol valerate injection

Key takeaways

HCPCS Code J1380 covers intramuscular injection of estradiol valerate (brand name Delestrogen), billed per unit of up to 10 mg.

One billing unit equals up to 10 mg, so a 20 mg dose is billed as 2 units.

NDC reporting is required by Medicaid and many commercial payers, and by Medicare only for dual-eligible crossover claims.

Medicare Part B pays J1380 at the average sales price plus 6%, and the rate updates every quarter.

Pabau’s claims management software keeps the treatment note, stock record and claim in one patient file, so units and codes match.

HCPCS Code J1380: Definition and code attributes

HCPCS Code J1380 is a Level II HCPCS drug code that describes injection, estradiol valerate, up to 10 mg, given by intramuscular route. The Centers for Medicare and Medicaid Services (CMS) maintains HCPCS Level II codes, including J1380, in its annual code set release.

Estradiol valerate is a prodrug of 17β-estradiol. Under the brand name Delestrogen, it is supplied as an oil-based injectable in 10 mg/mL, 20 mg/mL and 40 mg/mL strengths. J1380 applies only to the valerate ester given intramuscularly, not to oral tablets, patches, gels or other estrogen formulations.

What J1380 covers and what it excludes

J1380 covers only provider-administered intramuscular injections of estradiol valerate. Several formulations that look similar to coders fall outside this code.

• Covered: IM injection of estradiol valerate (Delestrogen) in any dose, billed in increments of up to 10 mg per unit.
• Not covered: Oral estradiol tablets of any brand. They are self-administered and not billable as a J-code.
• Not covered: Transdermal patches, gels, sprays or creams, because none of them is an injectable preparation.
• Not covered: Estradiol cypionate injection. That ester is reported under J1000, a distinct code.
• Not covered: Compounded estradiol valerate without an FDA-assigned NDC. Bill J3490 (unclassified drug) or J3590, depending on the payer, and expect coverage to be limited.
• Not covered: Other estrogen esters, such as estradiol benzoate or estradiol undecylate. Use J3490 or J3590 unless a specific code exists.

The most common coverage confusion is between J1380 and J1000. J1000 is estradiol cypionate, and J1380 is estradiol valerate. The two drugs share the same estradiol base but use different ester groups, release at different rates and carry different NDC numbers. Billing J1000 when Delestrogen was given, or the reverse, is a coding error to correct before the claim goes out.

Clinical indications and ICD-10 diagnosis codes for J1380

Medical necessity for J1380 is established through the diagnosis code on the claim. Payers use the ICD-10-CM code to decide whether the drug is indicated for the patient’s condition. The table below maps the most common clinical indications to their accepted diagnosis codes.

Always verify accepted diagnosis codes against the Medicare Administrative Contractor (MAC) Local Coverage Determination (LCD) for hormone therapy in your jurisdiction. Codes for gender-affirming care have changed across several fiscal year releases, so confirm that your code set is current.

How to bill J1380: Units, NDC and the administration code

Correct claim setup for J1380 takes three steps. Calculate the units, report the NDC in the proper format, and pair the drug code with the right administration code. Missing any one of them is enough to trigger a denial or an audit flag. Claims management software that supports injectable drug billing cuts the chance of a manual entry error on each element. A clean claim submission is always faster than working a denial.

The diagram below puts all five claim elements on one page, including the modifiers that usually stay off a Delestrogen claim.

Unit calculation

One billing unit of J1380 equals up to 10 mg of estradiol valerate. Bill units by dividing the administered dose by 10 and rounding up to the nearest whole number.

NDC reporting

NDC reporting is required by Medicaid and many commercial payers, and by Medicare for dual-eligible crossover claims (CR 7492). The Medicaid requirement comes from the Deficit Reduction Act of 2005. Report the NDC in 11-digit format (5-4-2 structure) on the claim line with qualifier N4. Follow it with the quantity dispensed and the unit of measure, typically ML for milliliters.

A missing or incorrectly formatted NDC is one of the most common administrative denials on J-code claims.

Administration code

96372 is the CPT code for a therapeutic, prophylactic or diagnostic injection given subcutaneously or intramuscularly. It’s billed alongside J1380 in an office setting and must appear on the same claim as the drug code. Some payers bundle it into a same-day E/M visit, so confirm the payer’s bundling policy before submitting both.

Medicare and commercial payer rates for J1380

Medicare Part B reimburses J1380 under the Average Sales Price (ASP) methodology. The payment amount equals ASP plus 6% in physician office settings. Because ASP comes from manufacturer-reported sales data, the J1380 rate updates every quarter. Verify the current rate in the CMS quarterly ASP Drug Pricing File before submitting claims or calculating expected reimbursement.

For commercial payers, the allowable amount is contract-specific and not publicly available. Most commercial plans reimburse injectable drugs at a percentage of Average Wholesale Price (AWP) or at a negotiated flat rate per NDC. The AAPC’s HCPCS code lookup gives code-level detail that helps when querying payer fee schedules.

Prior authorization requirements for J1380

Prior authorization (PA) requirements for J1380 vary by payer, plan type and clinical indication. Medicare Part B generally does not require PA for J1380 billed with a covered diagnosis, but Medicare Advantage plans may set their own rules. Most commercial payers require PA for ongoing hormone therapy.

Gender-affirming hormone therapy claims carry a heavier PA burden. Some plans want step therapy documentation, behavioral health letters of support, or diagnosis confirmation from a relevant specialist before they approve injectable estradiol.

• Typical PA documentation for menopausal HRT: a prescriber order with drug name, dose, route and frequency. Add a supporting diagnosis with lab values where applicable, plus clinical notes confirming symptom severity.
• Additional documentation for gender-affirming HRT: a gender dysphoria diagnosis (F64.0) and a letter of support from a qualified mental health or prescribing provider. Add evidence that payer-specific clinical criteria are met.
• PA reference number: once approved, record the authorization number in the patient’s chart and include it on every claim.

Never assume a prior authorization from one plan year carries forward. Confirm the authorization is active before each injection series, especially when a patient’s plan year resets.

Codes confused with HCPCS Code J1380

Four codes account for most J1380 substitution errors. Compounded preparations usually land on J3490, and the table below shows when each code applies.

Documentation requirements for J1380 claims

Complete documentation for J1380 covers both the clinical record and the claim itself. A single missing element can trigger an audit or a denial that delays payment by weeks. A well-structured superbill that captures each required field at the point of care keeps omissions off the claim.

• Prescriber order: drug name (estradiol valerate), dose in mg, route (intramuscular), frequency and prescriber signature.
• NDC on the claim line: 11-digit format, qualifier N4, quantity administered and unit of measure, wherever the payer requires it.
• Lot number and expiration date: required in the medical record for buy-and-bill dispensing, and may be requested on audit.
• Supporting diagnosis: an ICD-10-CM code documented in the clinical note that matches the claim.
• Administration documentation: injection site, technique and any adverse reactions observed.
• Prior auth reference number: if PA was required, include it on the claim and keep the authorization letter.
• Consent documentation: some payers require signed informed consent for ongoing hormone therapy, particularly in gender-affirming care.

Common J1380 claim denial reasons and how to fix them

Most J1380 denials are preventable. Denial management workflows for J-code drug claims follow a consistent pattern. Identify the CARC reason code, correct the source error, then resubmit or appeal with supporting documentation.

Modifiers used with J1380

JW and JZ became mandatory for single-dose containers under CR 12803 in 2023. GY and GX apply when a service is non-covered. Because Delestrogen is supplied only in 5 mL multiple-dose vials (10, 20 and 40 mg/mL), JW and JZ normally stay off a J1380 claim.

J1380 in gender-affirming and transgender care billing

Gender-affirming hormone therapy carries the most complex coverage picture of any J1380 indication. Unlike menopausal HRT, transgender HRT claims vary at the plan level, the state policy level and the payer network level at once.

The primary diagnosis code for gender-affirming estrogen therapy in MTF (male-to-female) patients is F64.0 (Transsexualism; inclusion term gender dysphoria in adolescents and adults). Some plans also accept Z87.890 (personal history of sex reassignment). Accepted codes differ by payer, so verify the preferred code with each one before submitting.

• Coverage variability: Medicaid coverage of gender-affirming drugs, including J1380, varies by state. Some state programs explicitly cover transgender HRT, while others require step therapy or impose quantity limits. Commercial plans differ even within one insurer, depending on the employer group contract.
• Prior auth burden: most commercial plans require PA for gender-affirming hormone therapy. PA documentation typically includes the F64.0 diagnosis, a prescriber order and a letter of support. That letter comes from a qualified provider, such as a psychiatrist, psychologist or primary care physician familiar with WPATH standards.
• Documentation best practice: keep a signed informed consent for gender-affirming hormone therapy in the patient record, since some payers request it at audit. Note the prescribing provider’s credentials and the clinical basis for the treatment decision.
• Step therapy: some commercial plans want evidence that oral estrogen was considered or tried before they approve injectable estradiol valerate. Document the clinical rationale for the injectable route, such as absorption concerns or patient preference supported by provider judgment.

Coverage and PA rules for gender-affirming care change often in response to state legislation and insurer policy updates. Practices billing J1380 for this population should review payer policies at least once a year and assign staff to watch for mid-year changes.

How Pabau keeps J1380 claims consistent from injection to payment

Most J1380 denials start with retyping. The dose sits in the treatment note, the NDC sits on the vial, and the diagnosis sits in the chart. A biller then copies all three into a separate claims tool, one field at a time.

Pabau keeps those pieces in one patient record instead. The treatment note, the vial logged from stock, the invoice and the claim sit together. Units and diagnosis codes are checked against the same visit.

The result is fewer resubmissions. Your team works errors from one dashboard instead of chasing remittances, and the days-overdue column shows which payer is holding money longest.

Submit clean J1380 claims the first time

Pabau keeps the treatment note, stock record and claim in one patient file, so J1380 units, NDC and diagnosis match before the claim goes out.

Book a demo

Conclusion

J1380 is a forgiving code once the setup is right. The descriptor is narrow, the unit math is simple, and Delestrogen’s multiple-dose vials keep wastage modifiers off most claims.

The risk sits in the payer rules around the code. Check NDC and prior authorization requirements before the first injection in a series, not after the first denial. For gender-affirming care, recheck coverage every plan year, because state rules and plan terms shift.

Book a demo to see how Pabau keeps dose, NDC and diagnosis in one record so your J1380 claims go out clean.

Continue your research

Billing estradiol cypionate instead? HCPCS code J1000 covers Depo-Estradiol units, NDC rules and the differences from J1380.

Waiting on a payer approval? The prior authorization process walks through each step from request to approval.

Need to understand denial codes on your remittance? Denial codes in medical billing explains CARC and RARC codes and how to respond to each.

Want a primer on the revenue cycle for injectable drug claims? What is revenue cycle management covers the end-to-end claim workflow from eligibility through payment posting.

Frequently asked questions